IRVINE, Calif., March 5, 2024 /PRNewswire/ — In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A (PureRec RNase A), a challenge that persisted for over half a century. This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
RNase A is a critical enzyme extensively utilized in plasmid and genomic DNA purification processes due to its efficacy in degrading RNA contaminants. It is traditionally sourced from bovine pancreases since the 1940s. However, when sourced from bovine origins, inherent risks of contamination are introduced. These risks encompass the potential presence of viruses, prions, and other undesired components from the animal source. Such contaminants can compromise the purity of plasmid and DNA samples, leading to failure in downstream applications. Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A. The use of PureRec RNase A ensures not only efficient RNA removal but also reduces the risk of potential introduction of animal-derived contaminants.
This transformative breakthrough is achieved by leveraging a cutting-edge protein expression approach and an efficient purification process. It overcomes the challenge of cytotoxicity when using a host expression system and ensures a consistent and high-quality supply of recombinant RNase A at a sustainable cost. It not only addresses the escalating awareness of contamination risks associated with animal-derived RNase A but also responds to the increasing demand for an ethically sourced, animal-free alternative.
PureRec RNase A was developed and manufactured in Zymo Research’s state-of-the-art facility in California, empowered by specialized expertise and advanced fermentation and bioprocessing technologies. Zymo Research’s innovative approach not only reduces the contamination risks and environmental impact associated with animal-based production methods but also ensures a secure and reliable supply chain for customers. The introduction of PureRec RNase A marks a transformative leap, revolutionizing the availability and accessibility of recombinant RNase A, unlocking unprecedented possibilities for researchers and industries alike.
For more information or bulk inquiries on Zymo Research’s recombinant RNase A, please check out PureRec RNase A.
About Zymo Research Corp.
Founded in 1994, Zymo Research is a privately-owned company with a strong focus on research and development, placing high value on innovation to create cutting-edge molecular tools tailored for the biotech sector. Guided by the motto "The Beauty of Science is to Make Things Simple," Zymo Research is renowned for its innovative products, spanning epigenetics to DNA/RNA purification technologies. Expanding beyond its historical leadership in epigenetics, the company is now revolutionizing sample collection, microbiome application solutions, recombinant protein and enzyme production, and next-generation sequencing (NGS) services. Zymo Research’s commitment to simplicity and high quality is evident in their user-friendly solutions, reflecting their dedication to advancing scientific processes. Follow Zymo Research on Facebook, LinkedIn, X (Twitter), and Instagram for the latest updates on their contributions to the field of biotechnology.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
